CCBR-SYNARC has a lineage that is rich in both science and clinical trials service. The company’s roots trace back over twenty years, to the research laboratories and clinical practices of several of the world’s leading experts in the use of medical imaging, subject recruitment and biochemical markers for evaluating new therapies. These research teams have coordinated hundreds of multi-center clinical trials and developed many of the medical image analysis methods, subject recruitment techniques and biochemical marker assays used today.
In the Spring of 1998, Drs. Harry K. Genant, Charles G. Peterfy and Thomas Fuerst from the Osteoporosis and Arthritis Research Group of the University of California San Francisco founded Advanced Imaging Research Services (AIRS). In October 1998, three leading university-based and two commercial-based operations merged with AIRS to form CCBR-SYNARC. This merger included three clinical-trials imaging groups (Oregon Osteoporosis Center, Imagine QMC and MDM Hologic) and two groups focused on biochemical markers services (CCBR and CLIOS). This brought together an unprecedented combination of medical and scientific expertise, and hands-on experience in imaging and molecular marker applications in clinical trials. In March 2004, CCBR-SYNARC opened its seventh office in Beijing China. In July, 2004, CCBR-SYNARC completed acquisition of IôDP Medical Imaging Company, and becomes CCBR-SYNARC's eighth office (CCBR-SYNARC Paris).
Working with CCBR speeds up and drives efficiencies in clinical trials by offering greater numbers of patients across fewer sites
A Global Footprint covering 16 dedicated Clinical Research Centers in high density population areas
Uniform SOPs enable the tightest possible adherence to study protocols and consistency across all CCBR sites
Real-Time tacking of subject enrolment and trial progress ensures sponsors have the most up to date information, all of the time
Centralised, standardised billing affords better visibility into trial costs for sponsors
